Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders: 2022-23 Data, Forecasts for 2024- 2026 and CAGR Projections through 2028
Dublin, Dec. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders" report has been added to * ResearchAndMarkets.com's* offering.
Neurological disorders are surging; this trend is particularly noticeable in syndromes associated with progressive ataxia and weakness disorders, such as Friedreich's ataxia, spinocerebellar ataxia and muscular dystrophy. The necessity for effective treatments has intensified as more individuals are affected by these conditions. Friedreich's ataxia, in particular, stands out as the most common form of hereditary ataxia, originating from genetic factors, impacting at least 1 in every 50,000 individuals.
According to the National MS Society, multiple sclerosis (MS) has a considerable presence in the United States, with an estimated one million people living with the condition. Society also reports approximately 25,000 new cases of MS diagnosed annually. As patients and healthcare professionals become more aware of these disorders, there is a growing demand for therapeutic interventions to address the challenges these debilitating conditions pose.
Key players in the global market for treatment for syndromes of progressive ataxia and weakness disorders are focused on authorizations and launches of innovative products to develop the portfolio. The product portfolio has a number of drugs used to treat multiple sclerosis, amyotrophic lateral sclerosis and hereditary neuropathies. These drugs are Kesimpta (ofatumumab), Gilenya, Exforge and Zolgensma (onasemnogene abeparvovec). The FDA approved Skyclarys (omaveloxolone) in Feb. 2023; it is the first treatment for Friedreich's ataxia, a rare inherited degenerative disease that damages the nervous system, characterized by impaired coordination and walking.
The market has seen strategic collaborations between pharmaceutical and product-development counterparts and thus some impressive candidates may hit the market in two to four years. Penetration is also being made into emerging markets, and more European markets are opening up. The major players in the market are Novartis AG, Pfizer, Sanofi, GlaxoSmithKline, Roche Holding Ltd., Merck & Co., Takeda Pharmaceuticals Ltd. and Abbott Laboratories.
The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. The report analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.
This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.
*The Report Includes*
· 34 data tables and 34 additional tables
· A comprehensive overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
· Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
· In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall market
· Estimation of the actual market size and revenue forecast for global progressive ataxia and weakness disorders treatments market in USD million values, and corresponding market share analysis based on product, technology, disease type, application, distribution channel, and region
· Discussion of the applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology
· Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market growth
· Review of key patent grants and recent patent applications on neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets, along with emerging technologies and new developments
· Coverage of recent merger and acquisition (M&A) activities, venture fundings, and other impactful growth strategies in the global market neurodegenerative (i.e., progressive ataxia and weakness) disorders
· Identification of the key players operating in the market, and analysis of their competitive landscape based on recent developments, segmental revenues, and operational integration
· Company profiles of major players within the industry, including Abbott Laboratories, Glenmark Life Sciences, Novartis AG, Pfizer Inc., Roche Holding Ltd., and Sanofi
*Key Attributes:*
*Report Attribute* *Details*
No. of Pages 180
Forecast Period 2023 - 2028
Estimated Market Value (USD) in 2023 $35.1 Billion
Forecasted Market Value (USD) by 2028 $57.2 Billion
Compound Annual Growth Rate 10.2%
Regions Covered Global*Key Topics Covered:*
*Chapter 1 Introduction*
*Chapter 2 Summary and Highlights*
*Chapter 3 Market Overview*
· Diagnostic Tests for Progressive Ataxia and Weakness Disorders
· Diagnostic Tests for Multiple Sclerosis
· Diagnostic Tests for Amyotrophic Lateral Sclerosis
· Diagnostic Tests for Friedreich's Ataxia
· Diagnostic Tests for Machado-Joseph Disease
· Diagnostic Tests for Hereditary Spastic Paraplegia
· Diagnostic Tests for Hereditary Neuropathies
*Chapter 4 Market Dynamics*
· Market Drivers
· Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
· Technological Advancements and Product Launch
· Increasing Expenditures for Health Care
· Rise in Alcohol and Drug Use
· Market Barriers
· Barriers to R&D for Progressive Ataxia
· Diagnostic Challenges
· Opportunities
· Advancements in Research and Technology
· Impact of Covid-19, Global Market for Treatment for Syndromes of Progressive Ataxia and Weakness Disorders
*Chapter 5 Market Breakdown by Type and Technology*
*Chapter 6 Market Breakdown by Disease*
*Chapter 7 Market Breakdown by Region*
*Chapter 8 Market Breakdown by Distribution Channel*
*Chapter 9 Emerging Technologies and Developments*
· Emerging Technology
· Stem Cell Therapy
· Gene Therapy
· Biomarkers
· Nasal Spray for MS
· Disease-Modifying Therapies
· RNA-Based Therapies
*Chapter 10 ESG Development*
*Chapter 11 Patent Analysis*
*Chapter 12 M&A and Venture Funding Outlook and Competitive Landscape*
*Chapter 13 Company Profiles*
· Abbott Laboratories
· Acorda Therapeutics
· American Regent
· Apotex
· Apotheca
· Astellas Pharma
· Astrazeneca
· Baxter International
· Bristol-Myers Squibb
· Eisai
· Eli Lilly
· Gilead Sciences
· GlaxoSmithKline
· Glenmark Life Sciences
· Johnson & Johnson
· Merck
· Novartis
· Pfizer
· Roche Holding
· Sanofi
· Takeda Pharmaceutical
· Teva Pharmaceutical Industries
For more information about this report visit https://www.researchandmarkets.com/r/67pod0
*About ResearchAndMarkets.com*
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
*Attachment*
· Global Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Market
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900